From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …

Integrins mediate cell adhesion and transmit mechanical and chemical signals to the cell
interior. Various mechanisms deregulate integrin signaling in cancer, empowering tumor …

Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genoty** and longitudinal disease monitoring. However, owing to past emphasis on …

Prostate cancer adeno-to-neuroendocrine lineage transition has emerged as a mechanism
of targeted therapeutic resistance. Identifying the direct molecular drivers and develo** …

Metastatic prostate cancer (mPC) comprises a spectrum of diverse phenotypes. However,
the extent of inter-and intra-tumor heterogeneity is not established. Here we use digital …

Inactivation of the RB1 tumor suppressor gene is common in several types of therapy-
resistant cancers, including metastatic castration-resistant prostate cancer, and predicts poor …

Prostate cancer is characterized by a high degree of heterogeneity, which poses a major
challenge to precision therapy and drug development. In this review, we discuss how …

Advances in omics technologies—such as genomics, transcriptomics, proteomics and
metabolomics—have begun to enable personalized medicine at an extraordinarily detailed …

Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine
prostate cancer (t-SCNC) are not well characterized in the era of modern androgen receptor …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …